|
| |
 |
Home
Technology
- Haloperoxidase
Enzymes
MPO and EPO provide the basis for safe, broad-spectrum microbicidal
agents against serious and resistant infections.
- Efficacy
and Safety
Pre-clinical studies indicate that MPO and EPO are non-toxic, non-irritating,
non-genotoxic, and non-sensitizing in various formulations.
Indications
- Nosocomial
Infections
Multiple MPO formulations are in development for prevention of serious,
and often resistant, hospital-acquired infections.
- Surgical
Site Infection
Our unique MPO formulation holds the promise of a breakthrough in surgical
site infection prevention.
- Biodefense
The MPO technology platform suggests the potential for use in preventing
infections in conventional and biological attack situations.
Collaborations
- Exoxemis
as a Partner
Applying highest quality science, research, and development to our partnerships
and collaborations.
- Lincensing
We leverage our proprietary know-how and technology platform through
product licensing and collaborations in areas of unmet clinical need.
Company
- Vision
and Values
The Exoxemis technology platform has the potential to change the paradigm
of infectious disease prevention and treatment by providing an alternative
to existing antibiotics and other anti-infectives.
- Intellectual
Property
We offer a comprehensive intellectual property portfolio in MPO and
EPO technologies protected by more than 20 patents worldwide.
Publications
- News
Exoxemis’ scientific team members are active contributors to the
field’s body of knowledge in MPO technology.
- Haloperoxidase
Literature
An extensive literature on haloperoxidases supports the broad microbicidal
activity of MPO and EPO.
Contact
Sitemap
|
|
|
| |
|
|
